7d agoSeeking AlphaBULLISH 63Analyst
TG Therapeutics: Why I'm Staying Long After The Q2 Selloff
TG Therapeutics, Inc. stays a Buy as BRIUMVI revenue jumps and 2026 guidance rises; subcutaneous Phase 3 is a catalyst. Click for this TGTX stock update.
Archived explainer. For the current picture see today's TGTX page.
Why Is TG THERAPEUTICS INC (TGTX) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 4, 2026 at 6:09 AM ET · reviewed against 12 wire stories
TG THERAPEUTICS INC (TGTX) is drawing unusual attention today. Our newswire has captured 12 stories on TGTX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why TGTX stock is moving today
TGTX stock is moving lower by 11% following the company's Q2 2026 earnings report. The decline comes despite a significant revenue beat and an upward revision of 2026 guidance. The primary driver of the selloff is the company's failure to meet earnings per share expectations.
What Happened
TG Therapeutics reported Q2 2026 earnings of $0.05 per share, missing the estimated $0.33. This shortfall triggered a sharp sell-off in the stock. However, the company reported strong BRIUMVI sales, which drove second-quarter revenue growth to $240.335 million, exceeding the estimated $229.721 million. As a result, the company raised its 2026 total global revenue target to around $950 million from $925 million previously. The CEO highlighted that BRIUMVI is on track to become a $1 billion US drug and noted that subcutaneous Phase III results are expected around year-end. Despite these positive developments, the earnings miss overshadowed the revenue beat and led to the stock's decline.
What The Data Shows
The stock has moved -2.7% over the last 8 sessions, from $53.27 to $51.81. The 52-week range is $25.28 to $59.30. The company's fundamentals show a market cap of $7.4 billion, a P/E ratio of 18.1, and a revenue growth of 81.3% trailing twelve months. The net margin is 66.0%, and the stock has a beta of 1.60. Recent congressional trades include two buys and two sells by Donald J. Trump, with the most recent filing on July 1, 2026.
What To Watch
The stock's next major catalyst will be the subcutaneous Phase III results expected around year-end. Investors should also monitor the coverage breadth and any further revisions to the company's guidance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TGTX by the numbers
7 sessions: -17.48%Coverage: 12 stories / 8 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $7.4BP/E: 18.152w: $25.28 to $59.30
The headlines behind the move
7d agoSeeking AlphaBEARISH 38Earnings
TG Therapeutics down 11% following Q2 bottom line miss
TG Therapeutics stock drops after Q2 EPS miss despite surging Briumvi sales and raised 2026 revenue guidance. Read more here.
7d agoSeeking AlphaBULLISH 71Earnings
TG Therapeutics targets $890M-$905M 2026 U.S. BRIUMVI net revenue while anticipating subcutaneous Phase III results around year-end
TG Therapeutics (TGTX) Q2 2026 earnings call: BRIUMVI revenue beat, raised 2026 guidance, and key IV/subcutaneous pipeline catalysts—read highlights now.
7d agoSeeking AlphaNEUTRAL 50Earnings
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call August 3, 2026 8:30 AM EDTCompany ParticipantsJenna Bosco - Senior Vice President of Corporate...
7d agoInvestors.comBEARISH 38Earnings
Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble
Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports.
7d agoStocktwits NewsBULLISH 63Product/PR
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.
7d agoInvestorsHubBULLISH 71Earnings
TG Therapeutics Raises 2026 Outlook Following Strong Briumvi Sales Growth
TG Therapeutics raised its 2026 revenue guidance after strong Briumvi sales drove second-quarter revenue growth, while the company also advanced multiple late-stage clinical programs.
7d agoInvesting.com MarketsBEARISH 42General
Why is TG Therapeutics stock sliding today?
Why is TG Therapeutics stock sliding today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TGTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TGTX move explainers: 2026-08-04 · 2026-08-03 · 2026-07-13